-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period fromto

Commission File Number: 001-40312

EQRx, Inc.

(Exact name of registrant as specified in its charter)

Delaware	86-1691173
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
50 Hampshire Street, Cambridge, MA	02139
(Address of principal executive offices)	(Zip Code)

(617)315-2255

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

		Name of each exchange
Title of each class	Trading Symbol(s)	on which registered
Common stock, par value $0.0001 per Share Warrants to purchase one share of common stock at an exercise price of $11.50	EQRX EQRXW	The Nasdaq Global Market The Nasdaq Global Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

Indicate by check mark whether the registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.0405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 5, 2022, the registrant had 448,141,108 shares of common stock, $0.0001 par value, outstanding.

TABLE OF CONTENTS

	Page
PART I – FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements (unaudited)	1
Condensed Consolidated Balance Sheets	1
Condensed Consolidated Statements of Operations and Comprehensive Loss	2
Condensed Consolidated Statements of Stockholders’ Equity	3
Condensed Consolidated Statements of Cash Flows	4
Notes to Condensed Consolidated Financial Statements	5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3. Quantitative and Qualitative Disclosures About Market Risk	37
Item 4. Controls and Procedures	37
PART II – OTHER INFORMATION
Item 1. Legal Proceedings	39
Item 1A. Risk Factors	39
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	39
Item 3. Defaults Upon Senior Securities	39
Item 4. Mine Safety Disclosures	39
Item 5. Other Information	39
Item 6. Exhibits	40
Signatures	41

In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to “EQRx,” “the Company,” “we,” “us,” “our” and similar references refer to EQRx, Inc. together with its consolidated subsidiaries. The trademarks of EQRx appearing in this Quarterly Report on Form 10-Q are the property of EQRx. This Quarterly Report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.

i

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of such terms or other similar expressions. All statements, other than statements of present or historical fact included in this Quarterly Report on Form 10-Q, our future financial performance, strategy, expansion plans, future operations, future operating results, estimated revenues, losses, projected costs, prospects, plans and objectives of management are forward-looking statements. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Forward-looking statements in this Quarterly Report on Form 10-Q may include, for example, statements about:

● our ability to realize the anticipated benefits from the Business Combination (as defined below), which may be affected by, among other things, the costs of the Business Combination, competition and our ability to grow and manage growth profitably and retain our key employees;

● the success, cost and timing of our product development activities;

● our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product;

● our ability to locate and acquire complementary products or product candidates and integrate those into our business;

● our ability to maintain our existing or enter into additional license agreements;

● our ability to maintain our existing or enter into additional drug engineering collaborations;

● our ability to maintain our existing or enter into additional manufacturing agreements;

● our ability to compete with other companies currently marketing or engaged in the development of innovative drug candidates, many of which have greater financial and marketing resources than we do;

● our ability to develop and maintain our Global Buyers Club;

● the size and growth potential of the markets for our products, and the ability of each to serve those markets, either alone or in partnership with others;

● changes in applicable laws or regulations;

● our ability to raise capital in the future;

● our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

● our financial performance;

● our ability to compete effectively in a competitive industry;

● our ability to protect and enhance our corporate reputation and brand;

● expectations concerning our relationships and actions with third parties;

● potential liquidity and trading of our securities;

● our ability to attract and retain qualified directors, officers, employees and key personnel; and

● the impact of the ongoing COVID-19 pandemic on us.

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements, including without limitation:

● We do not have any products approved for commercial sale and have not generated any revenue to date, and so may never become profitable.

ii

● Our business and pricing model are untested and may never be successful or generate sufficient revenue to lead to profitability.

● Our business model requires us to scale our pipeline through increasing our number of product candidates (by in-license, discovery alone or in partnership, or acquisition), and developing such product candidates, which we may be unable to successfully achieve or maintain.

● Our failure to manage growth effectively could cause our business to suffer and have an adverse effect on our ability to execute our business strategy, as well as operating results and financial condition.

● We may be unsuccessful in achieving broad market awareness and acceptance or changing prescribing or purchasing habits of healthcare system participants or keeping up to date with recent developments in the medical field regarding treatment options.

● We may be unable to continue to attract, acquire and retain third-party collaborators, including payers, collaboration partners and licensors, or may fail to do so in an effective manner. Our collaborations with third-parties are also subject to certain risks.

● Our financial projections are subject to significant risks, assumptions, estimates and uncertainties, and our actual results may differ materially.

● If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.

● We have never successfully completed the regulatory approval process for any of our product candidates, and we may be unable to do so for any product candidates.

● If regulators do not accept data from our license partners generated in other jurisdictions as a basis for regulatory approvals in our target markets, or we experience delays in obtaining data from our license partners, or we experience delays or difficulties in the initiation or enrollment of our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

● Our current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

● Even if we are successful in obtaining regulatory approval in one indication or jurisdiction for a product candidate, it does not guarantee that we will be able to obtain regulatory approval in any other indication or jurisdiction.

● Even if we receive regulatory approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.

● If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.

Additional discussion of the risks, uncertainties and other factors described above, as well as other risks and uncertainties material to our business, can be found under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 23, 2021, and we encourage you to refer to that additional discussion. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements.

Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect, and we cannot otherwise guarantee that any forward-looking statement will be realized. We hereby qualify all of our forward-looking statements by these cautionary statements.

Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated

iii

in these forward-looking statements, even if new information becomes available in the future. You are advised, however, to consult any further disclosures we make on related subjects.

iv

PART I – FINANCIAL INFORMATION

EQRx, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except share and per share information)

	June 30,		December 31,
	2022		2021
Assets
Current assets:
Cash and cash equivalents	$	864,436	$	1,678,542
Short-term investments		692,911		—
Prepaid expenses and other current assets		30,944		27,660
Total current assets		1,588,291		1,706,202
Property and equipment, net		1,516		1,985
Restricted cash		633		633
Right-of-use asset		4,889		2,672
Other investments		4,000		4,000
Other non-current assets		8,950		13,950
Total assets	$	1,608,279	$	1,729,442
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	13,019	$	7,640
Accrued expenses		39,617		28,904
Lease liability, current		2,619		3,102
Total current liabilities		55,255		39,646
Non-current liabilities:
Contingent earn-out liability		59,472		153,041
Warrant liabilities		15,984		21,115
Lease liability, non-current		2,645		272
Restricted stock repurchase liability		422		529
Total liabilities		133,778		214,603
Commitments and contingencies (note 14)
Stockholders' equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021		—		—
Common Stock, $0.0001 par value; 1,250,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 538,004,900 and 537,632,615 shares issued as of June 30, 2022 and December 31, 2021, respectively; and 474,077,426 and 469,369,433 shares outstanding at June 30, 2022 and December 31, 2021, respectively		49		49
Additional paid-in capital		1,896,797		1,873,289
Accumulated other comprehensive (expense) income		(2,025)		1
Accumulated deficit		(420,320)		(358,500)
Total stockholders’ equity		1,474,501		1,514,839
Total liabilities and stockholders’ equity	$	1,608,279	$	1,729,442

See accompanying notes to the condensed consolidated financial statements.

1

EQRx, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except share and per share information)

	Three months ended				Six months ended
	June 30,				June 30,
	2022		2021		2022		2021
Operating expenses:
Research and development	$	47,298	$	21,416	$	100,726	$	38,093
General and administrative		31,792		13,223		64,055		23,505
Total operating expenses		79,090		34,639		164,781		61,598
Loss from operations		(79,090)		(34,639)		(164,781)		(61,598)
Other (expense) income:
Change in fair value of contingent earn-out liability		(8,205)		—		93,569		—
Change in fair value of warrant liabilities		1,184		—		5,131		—
Interest income, net		4,091		19		4,273		163
Other (expense) income, net		(526)		94		(12)		92
Total other (expense) income, net		(3,456)		113		102,961		255
Net loss	$	(82,546)	$	(34,526)	$	(61,820)	$	(61,343)
Other comprehensive loss:
Foreign currency translation adjustments		9		—		16		—
Unrealized holding losses on short-term investments		(2,042)		—		(2,042)		—
Comprehensive loss	$	(84,579)	$	(34,526)	$	(63,846)	$	(61,343)
Net loss per share - basic	$	(0.17)	$	(0.11)	$	(0.13)	$	(0.19)
Net loss per share - diluted	$	(0.17)	$	(0.11)	$	(0.13)	$	(0.19)
Weighted average common shares outstanding - basic	473,058,458		318,272,186		471,849,487		314,903,264
Weighted average common shares outstanding - diluted	473,058,458		318,272,186		471,849,487		314,903,264

See accompanying notes to the condensed consolidated financial statements.

2

EQRx, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands, except share information)

												Accumulated Other
	Series A Convertible Preferred Stock			Series B Convertible Preferred Stock			Common Stock			Additional Paid-in		Comprehensive		Accumulated		Total Stockholders'
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Income (Loss)		Deficit		Equity
Balance at December 31, 2020	—	$	—	—	$	—	298,295,250	$	31	$	740,542	$	—	$	(258,491)	$	482,082
Issuance of Series B convertible preferred stock, net of issuance costs of $169	—		—	26,133,332		71,256	—		—		—		—		—		—
Retroactive application of recapitalization				(26,133,332)		(71,256)	16,385,591		2		71,254		—		—		71,256
Vesting of restricted common stock	—		—	—		—	2,280,370		—		26		—		—		26
Stock-based compensation	—		—	—		—	—		—		784		—		—		784
Net loss	—		—	—		—	—		—		—		—		(26,817)		(26,817)
Balance at March 31, 2021	—	$	—	—	$	—	316,961,211	$	33	$	812,606	$	—	$	(285,308)	$	527,331
Issuance of common stock	—		—	—		—					—		—		—		—
Vesting of restricted common stock	—		—	—		—	2,135,105		—		27		—		—		27
Stock-based compensation	—		—	—		—	—		—		1,016		—		—		1,016
Net loss	—		—	—		—	—		—		—		—		(34,526)		(34,526)
Balance at June 30, 2021	—	$	—	—	$	—	319,096,316	$	33	$	813,649	$	—	$	(319,834)	$	493,848
												Accumulated Other
	Series A Convertible Preferred Stock			Series B Convertible Preferred Stock			Common Stock			Additional Paid-in		Comprehensive		Accumulated		Total Stockholders'
	Shares	Amount		Shares	Amount		Shares	Amount		Capital		Income (Loss)		Deficit		Equity
Balance at December 31, 2021	—	$	—	—	$	—	469,369,433	$	49	$	1,873,289	$	1	$	(358,500)	$	1,514,839
Vesting of restricted common stock	—		—	—		—	1,992,005		—		59		—		—		59
Common stock issued upon exercise of stock options	—		—	—		—	18,286		—		40		—		—		40
Foreign currency translation adjustment	—		—	—		—	—		—		—		7		—		7
Stock-based compensation	—		—	—		—	—		—		12,906		—		—		12,906
Net income	—		—	—		—	—		—		—		—		20,726		20,726
Balance at March 31, 2022	—	$	—	—	$	—	471,379,724	$	49	$	1,886,294	$	8	$	(337,774)	$	1,548,577
Vesting of restricted common stock	—		—	—		—	2,343,703		—		49		—		—		49
Common stock issued upon exercise of stock options	—		—	—		—	353,999		—		466		—		—		466
Foreign currency translation adjustment	—		—	—		—	—		—		—		9		—		9
Stock-based compensation	—		—	—		—	—		—		9,988		—		—		9,988
Unrealized loss on available for sale securities	—		—	—		—	—		—		—		(2,042)		—		(2,042)
Net loss	—		—	—		—	—		—		—		—		(82,546)		(82,546)
Balance at June 30, 2022	—	$	—	—	$	—	474,077,426	$	49	$	1,896,797	$	(2,025)	$	(420,320)	$	1,474,501

See accompanying notes to the condensed consolidated financial statements.

3

EQRx, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

	Six months ended
	June 30,
	2022		2021
Operating activities:
Net loss	$	(61,820)	$	(61,343)
Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation		22,894		1,800
Depreciation expense		639		579
Net amortization of premiums and discounts on investments		(1,339)		—
Change in fair value of contingent earn-out liability		(93,569)		—
Change in fair value of warrant liabilities		(5,131)		—
Non-cash lease expense		(327)		767
Changes in operating assets and liabilities:
Prepaid expense and other assets		1,821		(11,395)
Accounts payable		5,550		6,504
Accrued expenses		11,914		2,258
Net cash used in operating activities		(119,368)		(60,830)
Investing activities:
Purchases of property and equipment		(162)		(295)
Purchases of investments		(693,614)		—
Net cash used in investing activities		(693,776)		(295)
Financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs		—		71,256
Offering cost paid in connection with Business Combination and PIPE Financing		(1,363)		—
Proceeds from issuance of common stock		401		345
Net cash (used in) provided by financing activities		(962)		71,601
(Decrease) increase in cash, cash equivalents and restricted cash		(814,106)		10,476
Cash and restricted cash, beginning of period		1,679,175		490,315
Cash and restricted cash, end of period	$	865,069	$	500,791
Supplemental disclosure of non-cash activities
Receivable due from stock option exercises	$	105	$	—
Purchases of property and equipment in accounts payable	$	8	$	—

See accompanying notes to the condensed consolidated financial statements.

4

EQRx, INC.

Notes to the Condensed Consolidated Financial Statements

1. NATURE OF BUSINESS

EQRx, Inc. (the “Company”), formerly known as CM Life Sciences III Inc. (“CMLS III”), was incorporated in Delaware on January 25, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. On December 17, 2021 (the “Closing Date”), the Company consummated the merger transaction contemplated pursuant to a definitive merger agreement dated August 5, 2021 (the “Merger Agreement”), by and among the former EQRx, Inc. (“Legacy EQRx”), CMLS III and Clover III Merger Sub, Inc. (“Merger Sub”). As contemplated by the Merger Agreement, Merger Sub merged with and into Legacy EQRx, with Legacy EQRx surviving the Merger as a wholly-owned subsidiary of CMLS III (such transactions, the “Business Combination”). As a result of the Business Combination, CMLS III was renamed EQRx, Inc., and Legacy EQRx was renamed EQRx International, Inc.  

Legacy EQRx was formed on August 26, 2019 and launched in January 2020 as a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices.

The Company’s mission is to improve health for all with great, innovative, affordable medicines so that people with life-changing or chronic conditions can gain access to the medicines they need, physicians can treat patients without barriers to prescribing, and health systems can afford to make those medicines available, without restrictions, to the populations they serve in a financially sustainable manner. This approach starts with assembling a catalog of medicines at significant scale, targeting some of the most innovative clinical opportunities and highest drug cost categories of today and tomorrow, with an initial focus on oncology and immune-inflammatory diseases.

Assuming it is successful in obtaining regulatory approval, the Company plans to offer its catalog of innovative medicines to payers and health systems at radically lower prices, through a simple and transparent pricing model without surprise price increases. The Company is assembling a Global Buyers Club by entering into strategic partnerships with private and public payers and health systems so they and the patients they serve can gain access to its future medicines, if approved, at radically lower prices. The Company will offer simple and transparent pricing models to provide an opportunity for dramatic savings in these high-cost drug areas. The Company’s current pipeline of product candidates includes two late-stage programs each in-licensed in 2020: aumolertinib (EQ143), a third-generation epidermal growth factor receptor (EGFR) inhibitor, and sugemalimab (EQ165, also known as CS1001), an anti-programmed death-ligand 1 (PD-L1) antibody.

The Business Combination was accounted for as a reverse recapitalization with Legacy EQRx being the accounting acquirer and CMLS III as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the condensed consolidated financial statements and accompanying notes represents the accounts of Legacy EQRx and its wholly-owned subsidiaries. The shares and net loss per common share prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio established in the Merger Agreement. For additional information on the Business Combination, refer to note 4 to these condensed consolidated financial statements.

Risks and Uncertainties

The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, identification of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, establishment of relationships with strategic partners, and the ability to secure additional capital to fund operations. Product candidates in-licensed and to be in-licensed, discovered alone or in partnership, acquired or developed will require significant research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require

5

significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance and reporting capabilities.

There can be no assurance that the Company’s ability to identify product candidates and subsequently research and develop those product candidates will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained both inside and outside the United States (“U.S.”), that any products developed will obtain necessary government regulatory approval, or that any approved products will be commercially viable. Even if the Company’s product identification and development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales, and the Company may be subject to significant competitive or litigation risks.

The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, additional strains of COVID-19 and where outbreaks occur, and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. These situations, or others associated with COVID-19, could cause delays in the Company’s clinical trial plans and could increase expected costs, all of which could have a material adverse effect on the Company’s business and its financial condition. The Company has implemented work-from-home and other policies, and is continuing to adapt to evolving federal, state and local health regulations. COVID-19 has not had a significant impact on the operations or financial results of the Company to date.

Liquidity

The Company has limited operating history and anticipates that it will incur losses for the foreseeable future as it builds its internal infrastructure, identifies and acquires product candidates, conducts the research and development of its product candidates, and seeks marketing approval for its late-stage programs. The Company had a net loss of $61.8 million for the six months ended June 30, 2022, which included non-cash income of $98.7 million resulting from the recognition of the contingent earn-out liability and warrant liabilities at fair value at June 30, 2022, as compared to a net loss of $61.3 million for the six months ended June 30, 2021. Prior to the Business Combination, the Company funded its operations with its initial public offering, and its subsidiary, EQRx International, Inc., funded its operations with borrowings under the convertible promissory notes it issued in October 2019 and from the sale of convertible preferred stock.

As of June 30, 2022, the Company had cash, cash equivalents, short-term investments and restricted cash of $1.6 billion and an accumulated deficit of $420.3 million. The Company expects that its cash, cash equivalents, short-term investments and restricted cash outstanding as of June 30, 2022 will be sufficient to fund its obligations for at least twelve months from the date of issuance of these condensed consolidated financial statements.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated interim financial statements and accompanying notes include the accounts of the Company and its wholly-owned subsidiaries EQRx, International, Inc., EQRx Securities Holding Corporation and an immaterial wholly-owned foreign subsidiary. All intercompany transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC").

6

Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and the related notes, which provide a more complete discussion of the Company’s accounting policies and certain other information. The December 31, 2021 condensed consolidated balance sheet was derived from the Company’s audited financial statements. These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial position as of June 30, 2022, its results of operations for the three and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of the Company’s common stock, the accrual of research and development and manufacturing expenses, stock-based compensation expense, the valuation of the contingent earn-out liability, and the fair value of warrants. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.

3. CASH, CASH EQUIVALENTS AND RESTRICTED CASH

The Company considers all highly liquid investments with an original or remaining maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents as of June 30, 2022 and December 31, 2021 consist of U.S. government money market funds and commercial paper (see note 5).

Amounts included in restricted cash consist of cash held to collateralize a letter of credit issued as a security deposit in connection with the Company’s lease of its corporate facility located in Cambridge, MA.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the applicable condensed consolidated balance sheet that sums to the total of the same such amounts shown in the condensed consolidated statement of cash flows (in thousands):

	June 30,
	2022		2021
Cash and cash equivalents	$	864,436	$	500,158
Restricted cash		633		633
Total cash, cash equivalents and restricted cash	$	865,069	$	500,791

7

4. BUSINESS COMBINATION

Summary of Business Combination

On December 17, 2021, Merger Sub, a wholly-owned subsidiary of CMLS III, merged with Legacy EQRx, with Legacy EQRx surviving as a wholly-owned subsidiary of CMLS III, a related party. Pursuant to the terms of the Merger Agreement, on the Closing Date, each outstanding share of issued and outstanding common stock and preferred stock of Legacy EQRx was converted into the right to receive 0.627 shares (the “Exchange Ratio”) of the combined entity’s common stock, par value $0.0001 per share (“Common Stock”), resulting in the issuance of a total of 343,060,309 shares of Common Stock. Additionally, on the Closing Date, each option to purchase common stock of Legacy EQRx became an option to purchase shares of Common Stock of the combined company, subject to adjustment in accordance with the Exchange Ratio.

The Company assumed 11,039,957 publicly-traded warrants (“Public Warrants”) and 8,693,333 private placement warrants issued in connection with CMLS III’s initial public offering (“Private Warrants” and, together with the Public Warrants, the “Warrants”). Each Warrant entitles the holder to purchase one share of the Company’s common stock, par value $0.0001, at an exercise price of $11.50 per share.

As of the Closing Date, each of the issued and outstanding shares of Class A common stock and Class B common stock (“Founders Stock”) of CMLS III automatically converted, on a one-for-one basis, into shares of Common Stock, and each of the issued and outstanding Private Warrants and Public Warrants automatically converted into warrants to acquire shares of Common Stock.

In connection with the Business Combination, CMLS III entered into agreements with existing and new investors to subscribe for and purchase an aggregate of 120.0 million shares of Common Stock (the “PIPE Financing”) that resulted in gross proceeds of $1.2 billion upon the closing of the PIPE Financing. The closing of the Business Combination was a precondition to the PIPE Financing.

The number of shares of Common Stock outstanding immediately following the consummation of the Business Combination was as follows:

	Shares
Common stock of CMLS III outstanding prior to Business Combination	69,000,000
Less redemption of CMLS III shares	(39,587,066)
Less Founders Stock forfeited	(4,840,628)
Common stock of CMLS III as of the Business Combination	24,572,306
Common Stock issued pursuant to PIPE Financing	120,000,000
Business Combination and PIPE Financing shares	144,572,306
Common stock issued in Business Combination to Legacy EQRx stockholders	343,060,309
Total shares of common stock issued immediately after Business Combination	487,632,615

The Business Combination has been accounted for as a “reverse recapitalization” in accordance with GAAP. Under the reverse recapitalization model, the Business Combination was treated as Legacy EQRx issuing equity for the net assets of CMLS III, with no goodwill or intangible assets recorded. Under this method of accounting, CMLS III was treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the merger, Legacy EQRx stockholders held a majority of the voting power of the combined company, Legacy EQRx comprised all of the ongoing operations of the combined entity, Legacy EQRx comprised a majority of the governing body of the combined company, and Legacy EQRx senior management comprised all of the senior management of the combined company.

8

Net Proceeds

In connection with the Business Combination, the Company received net proceeds of $1.3 billion from the merger and related PIPE Financing. The following table summarizes the elements of the net proceeds from the Business Combination and PIPE Financing transactions (in thousands):

	Recapitalization
Cash - CMLS III's Trust account and cash (net of redemptions)	$	158,160
Cash - PIPE Financing		1,200,000
Less transaction costs and fees paid as of the Closing Date		(53,596)
Proceeds from the Business Combination, net of transaction costs paid as of the Closing Date		1,304,564
Less transaction costs paid following the Closing Date		(1,363)
Net proceeds from the Business Combination	$	1,303,201

Earn-Out Shares

Following the Closing Date, holders of Legacy EQRx securities and options (“Earn-Out Service Providers”) are entitled to receive as additional merger consideration up to 50,000,000 shares of Common Stock (the “Earn-out Shares”), comprised of two separate tranches, for no consideration upon the occurrence of certain triggering events. Earn-Out Service Providers may receive a pro rata share of up to 35,000,000 additional shares of Common Stock if at any time between the 12-month anniversary of the Closing Date and the 36-month anniversary of the Closing Date (the “Earn-Out Period”), the Common Stock price is greater than or equal to $12.50 for a period of at least 20 out of 30 consecutive trading days (“Tranche 1”), and up to 15,000,000 additional shares of common stock if at any time during the Earn-Out Period the Common Stock price is greater than or equal to $16.50 for a period of at least 20 out of 30 consecutive trading days (“Tranche 2”).

Earn-Out Shares allocated to Earn-Out Service Providers who held equity securities not subject to any vesting conditions or restrictions as of the Closing Date of the Business Combination are accounted for in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”), as the Earn-Out Shares are not indexed to the  Common Stock. Pursuant to ASC 815, these Earn-Out Shares were accounted for as a liability at the Closing Date of the Business Combination and subsequently remeasured at each reporting date with changes in fair value recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The fair value of the Earn-Out Shares accounted for under ASC 815 was $240.1 million at the Closing Date and was recognized as a liability in the condensed consolidated balance sheet.

Earn-Out Shares allocated to Earn-Out Service Providers who held shares of common stock or options to purchase common stock that are subject to time-based vesting conditions or restrictions as of the Closing Date of the Business Combination are accounted for in accordance with ASC Topic 718, Share-Based Compensation (“ASC 718”), as the Earn-Out Shares are subject to forfeiture based on the satisfaction of certain service conditions. Pursuant to ASC 718, these Earn-Out Shares were measured at fair value at the grant date (the Closing Date) and will be recognized as expense over the time-based vesting period with a credit to additional paid-in-capital. The fair value of the Earn-Out Shares accounted for under ASC 718 was $43.4 million at the Closing Date.

9

5. FAIR VALUE MEASUREMENTS

Items Measured at Fair Value on a Recurring Basis

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis (in thousands):

	June 30, 2022
	Level 1		Level 2		Level 3		Total
Assets
Cash equivalents:
Money market funds	$	181,964	$	—	$	—	$	181,964
Commercial paper (due within 90 days)		—		680,470		—		680,470
Investments:
U.S. treasury bills (due within 1 year)		—		63,576		—		63,576
Commercial paper (due within 1 year)		—		629,335		—		629,335
Total financial assets	$	181,964	$	1,373,381	$	—	$	1,555,345
Liabilities
Contingent earn-out liability	$	—	$	—	$	59,472	$	59,472
Warrant liabilities		8,942		7,042		—		15,984
Total financial liabilities	$	8,942	$	7,042	$	59,472	$	75,456

	December 31, 2021
	Level 1		Level 2		Level 3		Total
Assets
Cash equivalents:
Money market funds	$	1,345,174	$	—	$	—	$	1,345,174
Commercial paper (due within 90 days)		—		329,345		—		329,345
Total financial assets	$	1,345,174	$	329,345	$	—	$	1,674,519
Liabilities
Contingent earn-out liability	$	—	$	—	$	153,041	$	153,041
Warrant liabilities		11,813		9,302		—		21,115
Total financial liabilities	$	11,813	$	9,302	$	153,041	$	174,156

In determining the fair value of its cash equivalents at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data. There were no changes in valuation techniques or transfers between fair value measurement levels for the periods presented. 

The fair value of the Public Warrants was based on observable listed prices for such warrants. The fair value of the Private Warrants is equivalent to that of the Public Warrants as they have substantially the same terms; however, they are not actively traded. The change in the fair value of the Warrants during the six months ended June 30, 2022 was as follows (in thousands):